CN107021909A - A kind of levo-oxiracetam crystal formation II preparation method - Google Patents
A kind of levo-oxiracetam crystal formation II preparation method Download PDFInfo
- Publication number
- CN107021909A CN107021909A CN201610067165.XA CN201610067165A CN107021909A CN 107021909 A CN107021909 A CN 107021909A CN 201610067165 A CN201610067165 A CN 201610067165A CN 107021909 A CN107021909 A CN 107021909A
- Authority
- CN
- China
- Prior art keywords
- hydroxyls
- oxo
- pyrrolidine ethanamide
- crystal formation
- activated carbon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pyrrole Compounds (AREA)
Abstract
A kind of levo-oxiracetam crystal formation II preparation method, the high-purity levo-oxiracetam prepared using S-4- chloro-3-hydroxybutanoic acid esters and sodium azide as initiation material, levo-oxiracetam crystal formation II is prepared by pH methods with hydrochloric acid/ammoniacal liquor again, optical purity greatly improves levo-oxiracetam crystal formation II product quality more than 99.9%.
Description
Technical field
The present invention relates to levo-oxiracetam, and in particular to a kind of levo-oxiracetam crystal formation II preparation method.
Background technology
Levo-oxiracetam, (No. CAS is 62613-82- to the entitled oxo-1-pyrrolidine ethanamide of (S) -4- hydroxyls -2 of chemistry
5) synthesis of Phosphorylcholine and phosphatidyl ethanolamine, can be promoted, promote brain metabolism, by blood-brain barrier to special nervous centralis road
There is stimulation, improve the ratio of ATP/ADP in brain, making the synthesis of protein and nucleic acid in brain increases, and can improve intelligence
The memory of energy impaired patients and learning functionality, and medicine is also acted in itself without direct vasoactive without central excitation, it is right
The influence of ability of learning and memory is a kind of lasting facilitation.
For the oxo-1-pyrrolidine ethanamide of (S) -4- hydroxyls -2 effectively is developed into medicine, it is necessary to which one kind, which has, is easy to system
Make and acceptable chemically and physically stability solid-state form, with promote its processing with circulation store.For enhancing chemical combination
For the purity and stability of thing, crystalline solid form generally to be preferred over armorphous form.The presently disclosed oxygen of (S) -4- hydroxyls -2
In generation, -1- pyrrolidine acetamide crystal formations had tri- kinds of crystal formations of I, II, III, and wherein crystal formation II has preferable stability.
CN102558013A discloses oxo-1-pyrrolidine ethanamide crystal formation II of one kind (S) -4- hydroxyls -2 and preparation method thereof, and (S) -
The crystallization after frozen water top is washed of the oxo-1-pyrrolidine ethanamide of 4- hydroxyls -2 obtains crystal formation II, and the crystal formation is in the θ of angle of diffraction 2
For 10.669,13.25,13.847,14.198,16.729,17.934,18.746,18.816,20.273,20.413,
21.431、21.617、21.663、23.38、24.324、24.415、26.069、26.107、27.901、28.621、28.925、
29.449th, 29.484,31.702,36.516,37.685, have diffraction maximum at 39.721 degree, according to the patented method prepare (S)-
The oxo-1-pyrrolidine ethanamide crystal formation II of 4- hydroxyls -2, the reaction time is 1~3 day, and is handled comparatively laborious.In order to meet
, it is necessary to develop a kind of technique simply, required time is short the need for medical industry, the easy oxo of (S) -4- hydroxyls -2 of post processing -
1- pyrrolidine acetamides II method.
The content of the invention
It is an object of the invention to provide the oxo-1-pyrrolidine ethanamide crystal formation II of one kind (S) -4- hydroxyls -2 preparation side
Method, this method preparation technology is simple, and required time is short, and obtained product chiral purity is high.
Technical scheme involved in the present invention is as follows：
The oxo-1-pyrrolidine ethanamide crystal formation II of one kind (S) -4- hydroxyls -2 preparation method, it is characterised in that use with
Lower step：
The oxo-1-pyrrolidine ethanamide of (S) -4- hydroxyls -2 is configured to the water-soluble of 80~200mg/mL with deionized water
Liquid, adds the hydrochloric acid solution of the amount equivalent to 2~3 times of materials of oxo-1-pyrrolidine ethanamide of (S) -4- hydroxyls -2, is warming up to 80
~95 DEG C of 2~3h of insulation, then add activated carbon decolorizing, filter, and filtrate mass concentration is adjusted for 20~25% ammonia spirit
PH to 5~6, suction filtration is dried and both obtained；The mass concentration of the hydrochloric acid solution is 30~37%.
The oxo-1-pyrrolidine ethanamide crystal formation II of (S) -4- hydroxyls -2 that the present invention is prepared is in the θ of angle of diffraction 2
10.669、13.25、13.847、14.198、16.729、17.934、18.746、18.816、20.273、20.413、21.431、
21.617、21.663、23.38、24.324、24.415、26.069、26.107、27.901、28.621、28.925、29.449、
29.484th, 31.702,36.516,37.685, there is diffraction maximum at 39.721 degree, it is consistent with the crystal formation that CN102558013A is disclosed.
The present invention opens the route of an oxo-1-pyrrolidine ethanamide monocrystalline of brand-new culture (S) -4- hydroxyls -2,
Hydrochloric acid with the oxo-1-pyrrolidine ethanamide of (S) -4- hydroxyls -2 of certain concentration Jing Guo certain concentration by adjusting pH value, into
Work(has been made the oxo-1-pyrrolidine ethanamide crystal formation II of (S) -4- hydroxyls -2, and the oxo -1- of (S) -4- hydroxyls -2 has been promoted significantly
The scientific research of pyrrolidine acetamide crystal formation and industrialized production.The present invention process time is short, and whole crystal formation culture is small no more than 4
When, for CN102558013A, preparation efficiency is greatly improved.
Above-mentioned activated carbon dosage is 0.01~0.02 times of the oxo-1-pyrrolidine ethanamide weight of (S) -4- hydroxyls -2.
Found in R＆D process, the obtained oxo-1-pyrrolidine ethanamide of (S) -4- hydroxyls -2 is inclined to crystal formation II purity
It is low, or even sometimes appearance amount is micro- but is difficult to the impurity that separates, such asIn order to ensure (S) -4- hydroxyls
It is prepared by the oxo-1-pyrrolidine ethanamide of base -2 II quality, preferably following methods.
The oxo-1-pyrrolidine ethanamide crystal formation II of one kind (S) -4- hydroxyls -2 preparation method, it is characterised in that first prepare
(S) oxo-1-pyrrolidine ethanamide of -4- hydroxyls -2, then prepares crystal formation II with pH methods, and reaction scheme is：
；Operating procedure is：
1), first S-4- chloro-3-hydroxyls ethyl butyrate is dissolved with cyclopentanol, sodium azide is then added at 120~130 DEG C
Lower reaction obtains intermediate compound I for 2~3 hours, and wherein S-4- chloro-3-hydroxyls ethyl butyrate and sodium azide mol ratio are 1：2~3；
2) intermediate compound I is dissolved with DMSO, carrying out reduction reaction with hydrogen by catalyst of Metal Palladium obtains intermediate II,
Reaction temperature is 10~40 DEG C, and the reaction time is 5~8 hours；
3) intermediate II is dissolved with tetrahydrofuran, potassium carbonate is catalyst, reacted 7~8 hours with bromoacetic acid N-butyl,
Reaction temperature is 50~60 DEG C；The mol ratio of the intermediate II and bromoacetic acid N-butyl is：1:1~2, intermediate II with it is described
The mol ratio of potassium carbonate is：1:2~3；
4) intermediate III is dissolved with ethanol, ring closure reaction is carried out under the conditions of 70~80 DEG C and obtains intermediate compound IV, is reacted
Time is 8~10 hours；
5) intermediate compound IV and ammoniacal liquor are reacted 13~18 hours at 20~30 DEG C, obtains the oxo -1- of (S) -4- hydroxyls -2
Pyrrolidine acetamide crude product, the intermediate compound IV：The mol ratio of ammonia is intermediate compound IV：Ammonia=1：12~15, it is molten with ammonia methanol
Ammonia meter in liquid, the concentration of the ammoniacal liquor is 25-28%；
6) the oxo-1-pyrrolidine ethanamide crude product of (S) -4- hydroxyls -2 is dissolved by heating in water, activated carbon decolorizing, filtered
Activated carbon is removed, be concentrated under reduced pressure water removal, stop concentrating when surplus water is adds 2~3 times of products weight, 0~5 DEG C of low temperature cold
But crystallize, obtain the oxo-1-pyrrolidine ethanamide of (S) -4- hydroxyls -2；
7) oxo-1-pyrrolidine ethanamide of (S) -4- hydroxyls -2 is configured to 100~150mg/mL water with deionized water
Solution, adds the hydrochloric acid solution of the amount equivalent to 2~3 times of materials of oxo-1-pyrrolidine ethanamide of (S) -4- hydroxyls -2, is warming up to
85~90 DEG C of 2~3h of insulation, then add activated carbon decolorizing, filter, and filtrate mass concentration is 20~25% ammonia spirit
PH to 5~6 is adjusted, suction filtration is dried and both obtained；The mass concentration of the hydrochloric acid solution is 30~37%；The activated carbon dosage is
(S) 0.01~0.02 times of the oxo-1-pyrrolidine ethanamide weight of -4- hydroxyls -2.
The present invention uses S-4- chloro-3-hydroxybutanoic acid esters and sodium azide to prepare the oxygen of (S) -4- hydroxyls -2 for initiation material
Generation -1- pyrrolidine acetamides, intermediate and product do not need the impurity for not produced in column chromatography, preparation process and being difficult to removeThe obtained oxo-1-pyrrolidine ethanamide product purity of (S) -4- hydroxyls -2 is examined through efficient liquid phase
Survey reaches more than 99.5%, and using this oxo-1-pyrrolidine ethanamide of (S) -4- hydroxyls -2 as raw material, pH is passed through with hydrochloric acid/ammoniacal liquor
Method prepares the oxo-1-pyrrolidine ethanamide crystal formation II of (S) -4- hydroxyls -2, and optical purity is greatly carried more than 99.9%
The high oxo-1-pyrrolidine ethanamide crystal formation II of (S) -4- hydroxyls -2 product quality；For CN102558013A, instead
Answer efficiency high, substantially shorten that (crystal formation culture of the present invention is no more than 4 hours, and CN102558013A is 1~3 day the time.
Brief description of the drawings
Fig. 1 is the oxo-1-pyrrolidine ethanamide crystal formation II of (S) -4- hydroxyls -2 powder diagram；
Fig. 2 is the oxo-1-pyrrolidine ethanamide crystal formation I of (S) -4- hydroxyls -2 and crystal formation II differential scanning calorimeter figure
(DSC)；
Fig. 3 is the oxo-1-pyrrolidine ethanamide crystal formation II of (S) -4- hydroxyls -2 infrared spectrum (IR) figure.
Embodiment
The present invention is specifically described below by embodiment, it is necessary to it is pointed out here that be that following examples are only used
It is further described in the present invention, it is impossible to be interpreted as limiting the scope of the invention, person skilled in art can
To make some nonessential modifications and adaptations to the present invention according to the invention described above content.
Embodiment 1
The oxo-1-pyrrolidine ethanamide of 1g (S) -4- hydroxyls -2 is dissolved with 10mL deionized waters, adding mass concentration is
30% hydrochloric acid solution, the amount of hydrochloric acid solution is the amount of 2 times of materials of the oxo-1-pyrrolidine ethanamide of (S) -4- hydroxyls -2, is risen
Then temperature adds 15mg activated carbon decolorizings to 85 DEG C or so insulation 2.5h, and filtering, filtrate mass concentration is molten for 25% ammoniacal liquor
Liquid adjusts pH to 5.5, and suction filtration is dried and both obtained.
The oxo-1-pyrrolidine ethanamide crystal formation of (S) -4- hydroxyls -2 is tested by X-ray powder diffraction by made from, as a result
Such as Fig. 1, diffraction maximum parsing such as following table：
The obtained oxo-1-pyrrolidine ethanamide crystal formation of (S) -4- hydroxyls -2 the θ of angle of diffraction 2 be 10.669,13.25,
13.847、14.198、16.729、17.934、18.746、18.816、20.273、20.413、21.431、21.617、21.663、
23.38、24.324、24.415、26.069、26.107、27.901、28.621、28.925、29.449、29.484、31.702、
36.516th, 37.685, there is diffraction maximum at 39.721 degree, it is consistent with the crystal formation II that CN102558013A is disclosed.
The infrared spectrum (see Fig. 3) that the obtained oxo-1-pyrrolidine ethanamide crystal formation II of (S) -4- hydroxyls -2 is produced with
Lower wave number shows absworption peak：
3318(cm-1)、3223(cm-1)、2929(cm-1)、2875(cm-1)、1680(cm-1)、1487(cm-1)、1402
(cm-1)、1276(cm-1)、1220(cm-1)、1078(cm-1)、968(cm-1)、943(cm-1)、694(cm-1)、611(cm-1)。
The oxo-1-pyrrolidine ethanamide crystal formation II of (S)-4- hydroxyls made from embodiment 1-2 is subjected to optical purity measure：
The oxo-1-pyrrolidine ethanamide crystal formation II of (S) -4- hydroxyls -2 is taken, precision weighs quantity (equivalent to containing (S) -4- hydroxyls
The oxo-1-pyrrolidine ethanamide 120mg of base -2) put 100ml measuring bottles, plus mobile phase ultrasonic dissolution and constant volume are made in every 1ml and contained
(S) the oxo-1-pyrrolidine ethanamide 1.2mg of -4- hydroxyls -2 solution, is used as need testing solution.
Precision measures solution 20ul, injects liquid chromatograph, records chromatogram, calculates unknown miscellaneous by area normalization method
The content of matter.
Determining chromatographic condition used is：
Instrument：Shimadzu LC-2010AHT high performance liquid chromatographs；
Work station title：LC-Solutio；
Chromatographic column：AGOP (4.6 × 100mm, 5 μm)；
Mobile phase:Acetonitrile：Phosphate buffer (pH6.0)=15:85；
Detection wavelength：210nm；
Flow velocity：1ml/min；
35 DEG C of column temperature；
Calculation formula is as follows：
In formula, Ai is the peak area of the oxo-1-pyrrolidine ethanamide of main ingredient active component (S) -4- hydroxyls -2；
∑ A is the peak area sum of S- configurations and the oxo-1-pyrrolidine ethanamide of R- isomers 4- hydroxyls -2.
Through three measurements, average, obtain the oxo-1-pyrrolidine ethanamide crystal formation II of (S) -4- hydroxyls -2 of embodiment 1
Optical purity be 99.93%.
For the crystal formation culture of the oxo-1-pyrrolidine ethanamide of (S) -4- hydroxyls -2 is carried out using pH methods, (S) -4-
The concentration of the oxo-1-pyrrolidine ethanamide aqueous solution of hydroxyl -2, the concentration of hydrochloric acid and the pH models of consumption, the concentration of alkali lye and adjustment
Enclose, possible different degrees of influence crystal formation cultivation results.(S) the oxo-1-pyrrolidine ethanamide concentration of aqueous solution of -4- hydroxyls -2
It is too low, then the oxo-1-pyrrolidine ethanamide powder of (S) -4- hydroxyls -2 or monocrystalline can not be obtained, excessive concentration then easily occurs brilliant
The mixture of type parcel and crystal formation I and crystal formation II.The concentration of hydrochloric acid is too low, and the oxo -1- pyrroles of (S) -4- hydroxyls -2 can not be made
Cough up alkyl acetamide crystal formation, the consumption of hydrochloric acid is excessive, then can cannot get the oxo-1-pyrrolidine ethanamide powder of (S) -4- hydroxyls -2 or
Person's crystal formation, or even cause the oxo-1-pyrrolidine ethanamide medicine of (S) -4- hydroxyls -2 to decompose.
Comparative example 1
The oxo-1-pyrrolidine ethanamide of 5g (S) -4- hydroxyls -2 is dissolved with 10mL deionized waters, adding mass concentration is
30% hydrochloric acid solution, the amount of hydrochloric acid solution is times amount of 2 materials of the oxo-1-pyrrolidine ethanamide of (S) -4- hydroxyls -2, is risen
Then temperature adds 15mg activated carbon decolorizings to 85 DEG C or so insulation 2.5h, and filtering, filtrate mass concentration is molten for 25% ammoniacal liquor
Liquid adjusts pH to 5.5, and suction filtration is dried and both obtained, detected by X powder diffraction, be found to be crystal formation I and crystal formation II mixture.Crystal formation I
Design parameter is referring to CN102249975A.
Comparative example 2
The oxo-1-pyrrolidine ethanamide of 1g (S) -4- hydroxyls -2 is dissolved with 10mL deionized waters, adding mass concentration is
30% hydrochloric acid solution, the amount of hydrochloric acid solution is times amount of 2 materials of the oxo-1-pyrrolidine ethanamide of (S) -4- hydroxyls -2, is risen
Then temperature adds 15mg activated carbon decolorizings to 85 DEG C or so insulation 2.5h, and filtering, filtrate mass concentration is molten for 25% ammoniacal liquor
Liquid adjusts pH to 4, and as a result suction filtration had not both obtained powder or do not obtained single crystal form material.
Tested with reference to comparative example 2, when pH is 1, medicine is decomposed；When pH is 2-4, powder was not as a result both obtained or had not had
Obtain single crystal form material；When pH is 9-13, both powder was not obtained or had not obtained single crystal form material；When pH is 14
When, medicine is decomposed.
Embodiment 2
(l) preparation of intermediate compound I：
Raw material S-4- chloro-3-hydroxyl methyl butyrate 5g are taken, is added in a single neck bottle, is added cyclopentanol 10ml, stir, add
Sodium azide 5g, 120~130 DEG C of keeping temperature is reacted 2 hours, and yellow solution is reacted to obtain in stopping.Water 20ml is added, acetic acid second is used
Ester 20ml is extracted, and concentration removes ethyl acetate, obtains yellow oil intermediate compound I.Detected through nuclear-magnetism, intermediate compound I is：1H-NMR
(300MHz,CDCl3):δ1.42-1.73(m,2H)2.76-2.67(AB system,m,2H,),3.31-3.23(AB
system,m,2H),3.75(s,3H),4.40(m,1H),3.70(s,1H).
Intermediate compound I is：
(2) preparation of intermediate II
The intermediate compound I that step (1) is obtained is dissolved in 50ml DMSO, is added 10% palladium-carbon catalyst 1g, is passed through hydrogen
In 10~30 DEG C of stirring reactions 5 hours under gas, point plate is shown in that raw material reaction is complete, stops reaction, and concentration removes solvent and obtains yellowish
Color grease intermediate II.Detected through nuclear-magnetism, intermediate II：1H-NMR(300MHz,D2O):δ2.76-2.67(AB system,
m,2H,),3.31-3.23(AB system,m,2H),3.75(s,3H),4.40(m,1H),4.70(bs,3H).13C-NMR
(50MHz,D2O):δ43.7(C-2),48.4(C-4),57.0(OCH,),68.9(C-3),177.5(C-I).
Intermediate II is
(3) preparation of intermediate III
The intermediate II that step (2) is obtained is dissolved in 50ml tetrahydrofuran, at 30 DEG C or so, adds potassium carbonate
17.3g (3eq), has a large amount of solids to generate, and stirs five minutes, starts that bromoacetic acid N-butyl 9ml (2eq) is added dropwise, dropwise addition process has
Continue to stir 7 hours after exothermic phenomenon, completion of dropping, point plate is shown in that raw material reaction is complete, stops reaction, adds EA (ethyl acetate)
50ml, water 30ml, solid is completely dissolved, by water layer solid sodium chloride saturation, separates organic layer, and water layer is extracted with EA 20ml
Twice, merge organic layer, organic layer is washed three times with 2M hydrochloric acid 20ml, merge hydrochloric acid aqueous phase, organic phase is discarded, aqueous phase carbonic acid
Hydrogen sodium adjusts pH to 8, and solid sodium chloride saturation, EA 30ml are extracted three times, merges organic phase, and anhydrous magnesium sulfate is dried, and concentration is removed
Solvent is gone to obtain pale yellow oil, curing at low temperatures obtains intermediate III.Detected through nuclear-magnetism, intermediate III：1H-NMR
(300MHz,D2O):δ1.3(t,3H),2.28-2.53(m,2H),2.58-2.83(m,2H)3.51(s,2H),3.67(s,3H),
4.09-4.12(m,3H).
Intermediate III is
(4) preparation of intermediate compound IV
The intermediate III that step (2) is obtained 50ml ethanol dissolves, and is warming up to 75 DEG C, flows back 8 hours, obtains one reddish brown
Color solution, point plate is shown in that raw material reaction is complete.Stop reaction, concentration removes ethanol, add EA (ethyl acetate) dissolvings, be filtered to remove
Salt, activated carbon decolorizing, concentration remove yellow oil obtains intermediate compound IV.Detected through nuclear-magnetism, intermediate compound IV is：1H-NMR
(300MHz,CDCl3)δ1.280(t,3H),2.38(dd,1H),2.69(dd,1H),3.34(dd,1H),3.77(dd,lH),
3.93(d,lH),4.18(d,1H),4.19(q,2H),4.30(bs,1H),4.50(m,1H).
Intermediate compound IV：
(5) preparation of the oxo-1-pyrrolidine ethanamide of (S) -4- hydroxyls -2
The intermediate compound IV that step (4) is obtained adds concentrated ammonia liquor (concentration is 25%) 20ml, is stirred at room temperature 15 hours, puts plate
See that raw material reaction is complete, stop reaction, water removal and ammonia are removed in concentration, obtain yellow oil, add acetone solution grease, plus
Enter a small amount of crystal seed to stir, precipitation solid, a small amount of acetone rinsing bottle wall, -10 DEG C crystallize 5 hours, are filtrated to get off-white color crude product
24g, chemical purity 99.0%.(6) by the dissolving crude product in 100ml water, heating dissolves it, and activated carbon decolorizing half is small
When, it is filtered to remove activated carbon, crystallisation by cooling, 5 DEG C stand overnight, and next day filters to obtain white solid 22g, chemical purity 99.5%,
Do not contained in productDetected through nuclear-magnetism, the oxo-1-pyrrolidine ethanamide of (S) -4- hydroxyls -2：1H-
NMR(300MHz,DMSO-d6)δ2.10(d,1H),2.57(dd,1H),3.69(d,1H),3.88(d,1H),4.10(d,1H),
The oxo-1-pyrrolidine ethanamide knot of (s, 1H) (the S) -4- of 4.31 (m, 1H), 5.25 (s, 1H), 7.13 (s, 1H), 7.33 hydroxyls -2
Structure formula is as follows：
(7) the oxo-1-pyrrolidine ethanamide crystal formation II of (S) -4- hydroxyls -2 preparation：
The oxo-1-pyrrolidine ethanamide of 2g (S) -4- hydroxyls -2 is dissolved with 10mL deionized waters, adding mass concentration is
35% hydrochloric acid solution, the amount of hydrochloric acid solution is the amount of 3 times of materials of the oxo-1-pyrrolidine ethanamide of (S) -4- hydroxyls -2, is risen
Then temperature adds 20mg activated carbon decolorizings, filtering to 90 DEG C or so insulation 3h, and filtrate mass concentration is 28% ammonia spirit
PH to 6 is adjusted, suction filtration is dried and both obtained；Verified by X powder diffraction method, it is identical with crystal formation II made from embodiment 1, and optical voidness
Spend for 99.94%.
Embodiment 3
The oxo-1-pyrrolidine ethanamide of 1.8g (S) -4- hydroxyls -2 is dissolved with 10mL deionized waters, mass concentration is added
For 34% hydrochloric acid solution, the amount of hydrochloric acid solution is the amount of 3 times of materials of the oxo-1-pyrrolidine ethanamide of (S) -4- hydroxyls -2,
95 DEG C or so insulation 3h are warming up to, 18mg activated carbon decolorizings are then added, filtering, filtrate mass concentration is molten for 25% ammoniacal liquor
Liquid adjusts pH to 5.8, and suction filtration is dried and both obtained；Verified with X powder diffraction method, obtained crystal formation is identical with the crystal formation II of embodiment 1,
And optical purity is 99.95%.
Embodiment 4
The oxo-1-pyrrolidine ethanamide of 1.2g (S) -4- hydroxyls -2 is dissolved with 10mL deionized waters, mass concentration is added
For 30% hydrochloric acid solution, the amount of hydrochloric acid solution is the amount of 2 times of materials of the oxo-1-pyrrolidine ethanamide of (S) -4- hydroxyls -2,
90 DEG C or so insulation 3h are warming up to, 15mg activated carbon decolorizings are then added, filtering, filtrate mass concentration is molten for 25% ammoniacal liquor
Liquid adjusts pH to 6, and suction filtration is dried and both obtained；Verified with X powder diffraction method, obtained crystal formation is identical with the crystal formation II of embodiment 1, and
Optical purity is 99.90%.
Embodiment 5
The oxo-1-pyrrolidine ethanamide of 1g (S) -4- hydroxyls -2 is dissolved with 10mL deionized waters, adding mass concentration is
35% hydrochloric acid solution, the amount of hydrochloric acid solution is the amount of 2 times of materials of the oxo-1-pyrrolidine ethanamide of (S) -4- hydroxyls -2, is risen
Then temperature adds 12mg activated carbon decolorizings, filtering to 85 DEG C or so insulation 2h, and filtrate mass concentration is 25% ammonia spirit
PH to 5 is adjusted, suction filtration is dried and both obtained；Verify that obtained crystal formation is identical with the crystal formation II of embodiment 1, and light with X powder diffraction method
It is 99.92% to learn purity.
Embodiment 6-8 is made with reference to embodiment 2, partial parameters are according to following operation：
(S)-Oxiracetam chemical purity made from embodiment 6-8 is high, wherein not containingOften
Chemical purity more than 99.5% can be achieved in rule purifying (being handled without column chromatography), as crystal formation of the raw material with reference to embodiment 1
Culture, is successfully made (S)-Oxiracetam crystal form II, and its optical purity is more than 99.90%.
Claims (3)
1. the oxo-1-pyrrolidine ethanamide crystal formation II of one kind (S) -4- hydroxyls -2 preparation method, it is characterised in that using following
Step：
The oxo-1-pyrrolidine ethanamide of (S) -4- hydroxyls -2 is configured to the 80~200mg/mL aqueous solution with deionized water, plus
Enter the hydrochloric acid solution of the amount equivalent to 2~3 times of materials of oxo-1-pyrrolidine ethanamide of (S) -4- hydroxyls -2, be warming up to 80~95
DEG C insulation 2~3h, then add activated carbon decolorizing, filter, filtrate mass concentration for 20~25% ammonia spirit adjust pH to 5
~6, suction filtration is dried and both obtained；The mass concentration of the hydrochloric acid solution is 30~37%；Oxo -1- the pyrroles of (S) -4- hydroxyls -2
Cough up alkyl acetamide crystal formation II the θ of angle of diffraction 2 be 10.669,13.25,13.847,14.198,16.729,17.934,
18.746、18.816、20.273、20.413、21.431、21.617、21.663、23.38、24.324、24.415、26.069、
26.107th, 27.901,28.621,28.925,29.449,29.484,31.702,36.516,37.685, have at 39.721 degree and spread out
Penetrate peak.
2. method as claimed in claim 1, it is characterised in that：The activated carbon dosage is the oxo -1- pyrroles of (S) -4- hydroxyls -2
0.01~0.02 times of alkyl acetamide weight.
3. method as claimed in claim 1 or 2, it is characterised in that：First prepare the OXo-1-pyrrolidine acetyl of (S) -4- hydroxyls -2
Amine, then prepares crystal formation II with pH methods, and reaction scheme is：
；
Operating procedure is：
1), first S-4- chloro-3-hydroxyls ethyl butyrate is dissolved with cyclopentanol, sodium azide is then added anti-at 120~130 DEG C
Answer and obtain within 2~3 hours intermediate compound I, wherein S-4- chloro-3-hydroxyls ethyl butyrate and sodium azide mol ratio are 1：2~3；
2) intermediate compound I is dissolved with DMSO, carrying out reduction reaction with hydrogen by catalyst of Metal Palladium obtains intermediate II, reacts
Temperature is 10~40 DEG C, and the reaction time is 5~8 hours；
3) intermediate II is dissolved with tetrahydrofuran, potassium carbonate is catalyst, reacted 7~8 hours with bromoacetic acid N-butyl, reaction
Temperature is 50~60 DEG C；The mol ratio of the intermediate II and bromoacetic acid N-butyl is：1:1~2, intermediate II and the carbonic acid
The mol ratio of potassium is：1:2~3；
4) intermediate III is dissolved with ethanol, ring closure reaction is carried out under the conditions of 70~80 DEG C and obtains intermediate compound IV, reaction time
For 8~10 hours；
5) intermediate compound IV and ammoniacal liquor are reacted 13~18 hours at 20~30 DEG C, obtains the oxo -1- pyrroles of (S) -4- hydroxyls -2
Alkyl acetamide crude product, the intermediate compound IV：The mol ratio of ammonia is intermediate compound IV：Ammonia=1：12~15, with ammonia methanol solution
Ammonia meter, the concentration of the ammoniacal liquor is 25-28%；
6) the oxo-1-pyrrolidine ethanamide crude product of (S) -4- hydroxyls -2 is dissolved by heating in water, activated carbon decolorizing is filtered to remove
Activated carbon, be concentrated under reduced pressure water removal, and concentration, 0~5 DEG C of sub-cooled knot are stopped when surplus water is adds 2~3 times of products weight
Crystalline substance, obtains the oxo-1-pyrrolidine ethanamide of (S) -4- hydroxyls -2；
7) oxo-1-pyrrolidine ethanamide of (S) -4- hydroxyls -2 is configured to the 100~150mg/mL aqueous solution with deionized water,
The hydrochloric acid solution of the amount equivalent to 2~3 times of materials of oxo-1-pyrrolidine ethanamide of (S) -4- hydroxyls -2 is added, it is warming up to 85~
90 DEG C of 2~3h of insulation, then add activated carbon decolorizing, filter, and filtrate mass concentration adjusts pH for 20~25% ammonia spirit
To 5~6, suction filtration is dried and both obtained；The mass concentration of the hydrochloric acid solution is 30~37%；The activated carbon dosage is (S) -4-
0.01~0.02 times of the oxo-1-pyrrolidine ethanamide weight of hydroxyl -2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610067165.XA CN107021909A (en) | 2016-01-29 | 2016-01-29 | A kind of levo-oxiracetam crystal formation II preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610067165.XA CN107021909A (en) | 2016-01-29 | 2016-01-29 | A kind of levo-oxiracetam crystal formation II preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107021909A true CN107021909A (en) | 2017-08-08 |
Family
ID=59523953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610067165.XA Withdrawn CN107021909A (en) | 2016-01-29 | 2016-01-29 | A kind of levo-oxiracetam crystal formation II preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107021909A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102558013A (en) * | 2011-08-11 | 2012-07-11 | 重庆润泽医疗器械有限公司 | (S)-4-hydroxy-2-oxo-1-pyrrolidine acetamide crystal form II and preparation method thereof |
| CN104230777A (en) * | 2013-06-19 | 2014-12-24 | 成都百途医药科技有限公司 | Synthetic method of oxiracetam |
-
2016
- 2016-01-29 CN CN201610067165.XA patent/CN107021909A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102558013A (en) * | 2011-08-11 | 2012-07-11 | 重庆润泽医疗器械有限公司 | (S)-4-hydroxy-2-oxo-1-pyrrolidine acetamide crystal form II and preparation method thereof |
| CN104230777A (en) * | 2013-06-19 | 2014-12-24 | 成都百途医药科技有限公司 | Synthetic method of oxiracetam |
Non-Patent Citations (1)
| Title |
|---|
| ENGIN SAHIN, ET AL.: "AN EFFICIENT SYNTHESIS OF (R)-GABOB AND OF (±)-GABOB", 《ORGANIC PREPARATIONS AND PROCEDURES INT.》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103553999A (en) | Preparation method of (S)-oxiracetam crystal form III | |
| CN105753904A (en) | Refining method for tedizolid phosphate | |
| CN102796079B (en) | A kind of preparation method of methanesulfonic acid fluorine imatinib | |
| CN106632267A (en) | Method for synthesizing voriconazole | |
| CN103070868B (en) | A kind of IDO inhibitor containing NH-1,2,3-triazole and preparation method thereof | |
| CN106431969A (en) | Method for preparing 2-methyl-4-formaldoxime methyl benzoate | |
| CN102690210A (en) | Novel crystal form VII of agomelatine, preparation method and application thereof and pharmaceutical composition containing the same | |
| CN103626697B (en) | A kind of preparation method of the cyanopyridine of 2 chlorine, 4 trifluoromethyl 3 | |
| CN104829673A (en) | Preparation method of sofosbuvir crystal form 6 | |
| CN107021909A (en) | A kind of levo-oxiracetam crystal formation II preparation method | |
| CN106632424A (en) | Copper chloride complex using 1-(2-pyridine)-9-hexyl-beta-carboline as ligand and synthesis method and application thereof | |
| CN107778224B (en) | Preparation method of betrixaban intermediate | |
| CN107011230A (en) | The method that pH methods prepare levo-oxiracetam crystal formation II | |
| CN107021901A (en) | (S)-oxiracetam crystal form II preparation method | |
| CN107021905A (en) | The method for preparing levo-oxiracetam crystal formation II | |
| CN103937866B (en) | A kind of preparation method of the ampicillin of improvement | |
| CN107021900A (en) | A kind of (S)-Oxiracetam crystal form II preparation method | |
| CN106632421A (en) | Copper nitrate complex of 1-(2-pyridine)-9-(4-methylbenzyl)-beta-carboline and synthesizing method and application of copper nitrate complex | |
| CN107021908A (en) | The method for preparing levo-oxiracetam crystal formation II | |
| CN107021899A (en) | A kind of method for preparing levo-oxiracetam crystal formation II | |
| CN107021907A (en) | Levo-oxiracetam crystal formation II preparation method | |
| CN107021896A (en) | A kind of levo-oxiracetam crystal formation II preparation method | |
| CN104557881A (en) | Preparation method of pazopanib hydrochloride crystal form | |
| CN107021904A (en) | The method for preparing levo-oxiracetam crystal formation II | |
| CN107021897A (en) | A kind of method for preparing levo-oxiracetam crystal formation II |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170808 |